The Technologies Set to Transform the Healthcare Sector

The healthcare sector in the UK is dominated by the National Health Service (NHS), which provides public sector medical support universally and employs more than 1.5 million people.

However, the NHS continues to face immense challenges in the current climate, largely in the form of chronic underfunding and waiting lists that have increased by more than 365-times since pre-pandemic reports in July 2019.

Some of these challenges are being tackled by technological advancement and innovation, to the benefit of both patients and workers. We’ll touch on some of these technologies below while asking how they’re likely to be beneficial.

#1. Telemedicine

Telemedicine describes the remote delivery of care and diagnostics, which has been made possible by technological innovation and accelerated by the impact of the coronavirus pandemic.

During the first months of the pandemic and associated global lockdowns, for example, the percentage of healthcare and doctor consultations that were carried out remotely increased from 0.1% to a staggering 43.5%.

Despite some concerns and teething issues, the majority of patients appear to be satisfied with this, meaning that telemedicine will become increasingly accessible and commonplace over time.

This also has huge benefits from a global perspective, as it makes healthcare and consultations far more accessible in developing regions of the world where there may be a shortage of doctors (such as Brazil, India and China).

#2. Artificial Intelligence (AI)

The global AI market is expected to reach a cumulative value of $136.6 billion in 2022, with this cutting edge technology offering value in a number of different applications.

This includes healthcare, with AI ideal for organising the huge swathes of unstructured data that’s available for capture and analysis. This is one of the principal uses of AI in any marketplace, with unstructured data historically difficult to collate and analyse.

In the healthcare setting, such datasets include medical image examples like MRI scans, X-rays and CT scans, alongside information on the global spread of communicable diseases such as Covid-19 (which can be drawn from across the globe).

AI is also being used to upskill human workers in medical fields, while augmenting complex procedures through the use of advanced computer vision and cameras.

#3. 5G Connectivity

5G connectivity has been a huge gamechanger in the worlds of commerce and healthcare, primarily by delivering downloads that are at least 10x faster than existing 4G services. This means that surgeons are now capable of performing remote surgeries on patients without even being present at the operating table.

5G also provides improved bandwidth and incredibly low levels of latency, making concepts such as the Cloud and Internet of Things (IoT) increasingly accessible for healthcare practitioners.

This is key, especially when you consider the complex regulatory framework that encompasses the healthcare sector and role that a technology lawyer plays in ensuring compliance over time.

5G can help to streamline the flow of information and documentation within the sizable healthcare network in the UK, boosting efficiency while ensuring a better service for patients.

Some Used Industrial Tanks Deemed Safe for Pharmaceutical Processing Industry

Some Used Industrial Tanks Deemed Safe for Pharmaceutical Processing Industry

Tanks are used by the pharmaceutical processing industry for biomedical and pharmaceutical applications in various ways, but they’re mostly used for mixing and storing chemicals and chemical compounds.

Therefore, it’s critical that industrial tanks used in the pharmaceutical industry are deemed safe to use.

Tanks Need to Be Clean, Disinfected, or Sterilised for Use in the Pharmaceutical Processing Industry

The number one reason why tanks need to be deemed safe to use is that they need to facilitate the safe handling of harsh chemicals and prevent contamination and leaching from happening.

Just as medical and surgical instruments need to be disinfected and sterilised to ensure infectious pathogens aren’t transmitted to patients, a high level of disinfection and sterilisation needs to be achieved when using tanks in the pharmaceutical industry.

Healthcare policies are in place to ensure tanks are cleaned, disinfected, or sterilised based on the intended use of the tanks.

Types of Tanks

Used industrial tanks are available in materials like polyethylene, fibreglass, carbon steel, and stainless steel. Buy stainless steel and plastic tanks are best-suited and most used in the pharmaceutical processing industry.

Each offers unique advantages for specific applications, such as storage, mixing, and research purposes. So, when choosing a tank, the precise application demands need to be carefully evaluated in order to find the right choice of material.

If you need to select tanks for pharmaceutical processing usage, this used industrial tanks list contains tanks that are considered to be safe for use.

Stainless Steel Tanks

There are advantages to using both stainless steel tanks and plastic tanks, so let’s take a look at both in more detail.

Stainless steel tanks are primarily used for mixing applications that need pressure or vacuum ratings, though stainless steel tanks can also be used for storage and processing.

Because stainless steel tanks are resistant to breakages when they’re exposed to cold or hot temperatures, they’re the ideal choice for specific cooling and heating applications.

Stainless steel tanks are also highly resistant to rough materials, unlike plastic tanks. Furthermore, stainless steel tanks can be better than plastic tanks in many situations because the former has high corrosion resistance and high strength and durability.

Stainless steel tanks are also hygienic, recyclable, and reduce reactivity in chemical treatments. On the downside, they require periodic maintenance because seams and welding points are vulnerable to crevice corrosion, chemical attacks, and pitting, over time.

Also, protective coatings for stainless steel tanks can be expensive. Indeed, the tanks themselves are typically more expensive to manufacture than plastic tanks.

Plastic Tanks

Plastic tanks are manufactured using high-density polyethylene, polyvinylidene, polypropylene, Teflon, and other types of plastics.

When the right plastics are used to make tanks for the pharmaceutical processing industry, they offer significant chemical resistance. Therefore, they often make ideal choices for chemical and liquid storage in pharmaceutical and biomedical applications.

Furthermore, plastic tanks are less expensive than stainless steel tanks, they’re lighter, and they’re easy to install. Another major benefit of plastic tanks is that they can be transparent, which means workers can easily see what the material levels are in tanks at any given time.

Plastic tanks also require less maintenance and they typically have a service life of twenty years or more.

The main drawback of plastic tanks is that they’re more vulnerable to extreme temperatures, so they’re not suited to applications in the pharmaceutical processing industry that involve intense cooling and heating applications.

Summing Up

Some industrial tanks are deemed safe for the pharmaceutical processing industry. The two most commonly used tanks are stainless steel and plastic tanks.

If you’re planning on using tanks for pharmaceutical purposes, make sure you spend time determining what they will be used for so that you can select the right thanks for your needs.

Now you know all about industrial tanks, you may be interested in learning about outsourcing the pharmaceutical product lifecycle.

ARYA BioMed product

Allowing Clients to Breathe Freely

ARYA BioMed product

Having become well known for the sale of exemplary, innovative, and portable oxygen concentrators, ARYA BioMed has recently received the award for the ‘Best Oxygen Concentrator Manufacturer’ in 2022 for the USA. Available through multiple retailers, one of which – SpryLyfe – is partnered with E-Learning providers, it has been showing its dedication to education and client health at every turn, with each item that it stocks making itself a reliable and highly rated element of an end customer’s healthcare routine. Over time, its reputation has been further bolstered by the lightweight and discrete nature of its products, allowing clients to find the best oxygen concentrator for them.

Selling portable oxygen concentrators, ARYA BioMed’s products have become well known for their ability to slow the progression of COPD and enhance the client’s overall control over their own healthcare. Its lightweight and portable design is one that its customers have lauded as exemplary since its beginnings, as it has always been driven by the premise of giving a client their livelihood back by ensuring that they need not spend their days tethered to cumbersome machines that need constant refilling and readjustment. Nominally, this care and commitment that is shows at every turn has set it apart from its peers and enhanced its reputation as a truly client-first business.

After all, more than just selling an oxygen concentrator, ARYA BioMed is selling an opportunity to regain self-sufficiency. This has been shown time and again through the glowing reviews and positive referrals that its clients leave it, lauding its helpful resources and exemplary product for allowing them to regain some control over the treatment and management of their COPD illness. One client talks of how they have been through many different healthcare options and facilities for their COPD, but that ARYA BioMed’s oxygen concentrator has been the first real help they have received in terms of easing the difficulties with breathing.

Moreover, it encourages clients to get in touch with its staff, allowing a genuine connection that is fostered over the course of a conversation through phone or email. Each of its staff members have been highly trained both in the art of customer service and in the specifics of its stock, from the newest features of the newest products to the technology that drives every one of them, and the ingenuity behind this. Critically, as the premium manufacturer for portable oxygen concentrators, the elements that have allowed it to secure and maintain this premium position in the market are its lightweight and compact form – allowing a client to bring their oxygen with them with ease – as well as an outstanding battery life and virtually silent operation. This is all part of ARYA BioMed’s dedication to discretion and lifestyle improvement. Designed and assembled in the USA, the concentrators weigh up to 5 pounds, have 5 different flow settings, and have a battery life that can last up to 16 hours. Moreover, at a mere ten inches in height, it promises to help give its clients back the freedom and independence that is so often stripped from those struggling with pulmonary diseases, as they find it so much harder to commit to long periods of activity and movement.

Therefore, it has dedicated itself to creating something that is useful in any situation. From travel to relaxation, running errands, or partaking in the hobbies that a client loves to do, it negates the need for refilling from cumbersome oxygen tanks, and allows access to medical grade oxygen any time a client needs it. The small, light, and non-invasive design is also FAA approved for use aboard aircrafts, allowing clients to travel across both state and country lines, ensuring they don’t have to miss another vacation, event, or family gathering.

Ensuring the utmost comfort in travel by allowing them to bring their concentrators on planes and along for long car rides, it is compact, ergonomic, and comfortable to wear: each of these fits itself nicely around the everyday lives of its customers, allowing them to get back into the activities they miss. Whether a client is old or young, ARYA BioMed will make itself an integral element of their peace of mind. Moreover, to this end, each machine comes with a lifetime warranty that shows the company’s true dedication to its clientele, their happiness, and their health, as it promises to go above and beyond to keep their oxygen concentrator working well.

Regarding the concentrator itself, the warranty is truly lifelong, and even the sieve bed has a warranty of 5 years. Both of these things ensure that customers can live their lives with the utmost peace of mind, able to trust in the excellence of the machinery, and the knowledge that should anything go awry, ARYA BioMed will not rest until the issue is resolved. Moreover, with the rest of the industry in the wider scale offering 3 year warranties of concentrators of 1 year warranties on sieve beds, it is easy to see why ARYA BioMed has become the no-brainer solution for so many people.

Between the lack of need for refills, the perfect performance during at-home use and use on the go, and the incredible level of dedication that its staff display when ensuring that its customers can buy with confidence, it has maintained a reputation for being far superior to every other oxygen delivery device. Indeed, the pulse flow operation that it operates with pairs well with its non-invasive and ergonomic design, making for a non-intrusive oxygenation solution that offers unmatched levels of freedom at every turn, and it is excited to bring this to many more clients in the future as it continues to expand its reach.

For business enquiries, contact Andy Flynn from ARYA BioMed on their website –

forget about age cosmetics products

Internationally Renowned Skincare with German Pedigree

forget about age cosmetics products

Having been founded in the latter months of 2018, Forget About Age Cosmetics is a German company that has earned accreditation as the ‘Most Innovative Anti-Ageing Cosmetic Brand’ in 2022 for its nation. With top of the range cosmetics, exemplary customer service, and a penchant for building great relationships with clients, it only develops products that are free of parabens, micro plastics, silicones, fragrances, and other inorganic substances.

A company that encourages its clients to embrace the ethos denoted by its name, Forget About Age Cosmetics has become a front runner in modern cosmetic product creation and development by upholding the strictest quality standards. Nominally, it promises to always go above and beyond to ensure the best of quality control for its clients, setting itself up as a deeply innovative and ingenuity fuelled cornerstone of the industry that seeks to lead by example. Based in Germany, it has offices in Italy and Austria as well as its home nation, allowing it to grow its European market as it strives to improve the appearance of its clients’ skin and their confidence in their own skin both.

Its products, therefore, are holistic and well-researched, all of them working together to bolster the client’s skincare regimen to be the best and most fitting for their skin type. One of the most important elements of skincare, it has found through its years of research, is collagen. By ensuring that a client has good levels of collagen, the client will find it easier to work towards healthier, more youthful, and more elasticated skin that is able to bounce back from the hardships of everyday life, aided by Forget About Age Cosmetics’ food supplement product that has proven to be a direct way to increase collagen levels.

Alongside the collagen boost, this supplement also provides a strong anti-oxidative substance called Pycnogenol, as well as Q10, Biotin, and Panthenol – the latter of which has become known as ‘skin perfect’ in cosmetic circles for its ability to replenish a youthful look and feel. Its wrinkle eraser, high SPF skincare, instant hydration serum, and eyecare have each made for an exemplary business relationship between it and its clients, as the products do an excellent job of speaking for themselves when it comes to what they offer clients. Thus, it has become a well-stocked favourite, sold through clinics, aestheticians, cosmetic clinics, and more, aiding the recovery of those who have undergone skincare treatments as well as becoming a cornerstone part of clients’ everyday skincare regime.

Instant Teint Love supports the healing and protection of fragile and healing skin, where Instant Hydration Serum helps to replenish the skin’s natural oils, and Instant Wrinkle Eraser works to smooth out those fine lines in order to give skin a dewy, youthful look. Its Instant Eyes Love also aids clients in getting rid of dark circles and fine eye wrinkles, as it knows that this is a stressor for a lot of people who work busy jobs and hectic lives in the hustle and bustle of the modern world. Despite the issues that have come about due to the pandemic – such as higher prices for raw materials, closing cosmetic clinics and other such establishments, and more – it has been able to use the exemplary reputation it has developed in its market segment to remain afloat. After all, its customers’ level of trust in its products ensured that they were keen to remain loyal to the brand, and it has repaid this loyalty in trust and enthusiasm, serving clients with the same level of diligence and tenacity that they came to expect prior to the pandemic as standard. Moreover, it has been working hard to create strong working relationships with its clients as a result, ensuring that it and its professional peers can form a solid network that allows the best service.

In essence, its commitment to client and customer base – as well as to its wider industry – has ensured that it can continue to develop a highly positive image for itself within the sector of cosmetic products, utilising the ‘made in Germany’ tag that comes with each of its products to also secure the country in international cosmetic renown. Indeed, Germany as a country tends to be synonymous with a level of attention to detail that is highly sought after in its engineering, and Forget About Age Cosmetics wishes to show that it is just as diligent in other industries, too.

Having been appreciated by clients all over the world for years, Forget About Age Cosmetics is excited to be creating bigger and better products as it moves forward towards the future. Critically, in a time where innovation is happening daily in the global cosmetic industry, it hopes to work with tenacity and scientific rigour in order to secure its place at the head of the pack, leading the way towards skincare solutions that grow and develop with the wider cosmetic world.

This is the commitment that Forget About Age Cosmetics has made to its clients with every serum, moisturiser, and eye cream that comes out of its production line. Testing each product for quality and excellence before it is sent out into the world, clients of Forget About Age Cosmetics can expect the most effective and kind-to-skin products that will come highly recommended by their clinicians and technical skincare experts, and the company is excited to announce that this entire production process to Germany in 2023. With this on the horizon, a multitude of conference attendances planned, and a whole new website slated for launch in 2023 alongside its new facilities, it hopes to secure partnerships in areas like Romania, Dubai, Lebanon, and more, continuing to push towards greater expansion in order to bring its exemplary products to more people.

For business enquiries, contact Astrid Tomczak from Forget About Age Cosmetics on their website –

How is IT Service Management Helping Improve the Healthcare Industry?


The healthcare sector is one of the industries today that is largely driven by knowledge. It is also one of the most evolving industries where the quality of care for patients largely depends on knowledge, support, and the tools available to healthcare organizations.

With the adoption of an IT service management system, healthcare organizations can foster a culture that involves continuous innovation and cooperation, creating an efficient flow of resources and information between patients, staff, and healthcare providers.

This means that IT Service Management (ITSM) is playing a vital role in the success of the healthcare industry. But what is it and how is it helping improve this industry?

What is IT Service Management (ITSM)?

ITSM can be defined as the process used by employees to manage IT service delivery. A team working on ITSM infrastructure is tasked with a lot of responsibilities, some of them including overseeing servers, applications, and employee laptops. They are also tasked with creating, designing, managing, and supporting all IT services.

ITSM in healthcare plays a crucial role when it comes to improving patient care, reducing human error, and mitigating risks. Information technology has given birth to service management tools that are breaking down the silos that would otherwise hurt the patient experience.

Efficient ITSM is very important in the healthcare industry because a slight error can lead to disastrous consequences. For instance, a wrong diagnosis can lead to other complications or even the death of patients.

How IT Service Management is Improving the Healthcare Industry

Performance Analysis

Every employer needs to implement a platform through which they can analyse the performance of their employees. This is the only way for them to improve departments that are failing and offer better services.

Similarly, healthcare providers need a system that allows them to analyse their performance and address healthcare staffing challenges. Fortunately, ITSM comes with different avenues through which they can analyse patient care, assess the performance of their employees, and analyse their services.

Improves Patient Safety and Care

Medical errors are among the most serious problems that face healthcare providers. They are also among the leading causes of death among patients in the world. This makes it a little bit difficult for providers to consistently identify the cause of errors.

In addition, those that succeed in identifying the cause of errors find it difficult to provide long-lasting solutions that can eliminate these errors for good. Fortunately, this is slowly changing because of ITSM.

ITSM is providing easier and faster access to information and patient data, ensuring that healthcare providers can not only collect data but also share it to ensure that they have improved patient safety. With this information, they can provide care personalized to address the different requirements of their patients.

Improves the Satisfaction of Patients

Efficient management of services and information in the healthcare industry is critical in improving the satisfaction of patients and adding value to all clinical processes. This is something that every healthcare provider should strive to achieve.

Through the use of ITSM, the workload demands among staff members are reduced. This ensures that the staff members have more time to address the demands of their patients and ensure that they (the patients) have everything that they need.

If your patients get personalized service and attention, they will be confident with you, something that enhances your reputation. ITSM also allows patients to get easy access to their health records and enhances payment processing, communication, and appointment booking.

Improves Patient Monitoring

With easier access to patient medical records using ITSM, healthcare providers can improve service delivery and patient care. This is essential when it comes to improving patient monitoring as well.

If a patient is suffering from a chronic condition that requires the intervention of doctors, then remote monitoring might be required. Remote monitoring requires a constant flow of information and accurate records to help the patients recover.

Through ITSM, healthcare providers can use the patient information they have in their databases to prevent and predict any health conditions that might affect their patients. They can also follow up with patients without having to visit them physically.

IT Service Management is not only changing the healthcare sector but also organizing daily tasks, making them easier, increasing efficiency, and improving patient experiences. Both patients and healthcare practitioners now have a system that they can rely on for their interactions.


Over 20 Years Later – Why the 911 Death Count Continues to Climb

September 11th, 2001 is a date that will live on in the United States, and it is also a date that has shaped a lot of what the United States and the world have done since. While 2,977 people were killed and over 6,000 were injured on that day, the deaths and the aftershocks of 9/11 haven’t faded, even as 9/11/2022 is coming up.

The 9/11 death count is continuing to climb among the first responders who bravely went into the World Trade Centre and the Pentagon to rescue as many people as they could, as well as those who cleaned up the aftermath at ground zero in the days and weeks after the event. But why are people continuing to die over 20 years later?


Hazards After The Destruction

The debris of the twin towers, as well as the smoke and fumes around the towers as they fell, got into the lungs of thousands of first responders. Additionally, many people were injured, lost limbs, and got infections from injuries sustained during the attack. The survivors and responders inhaled noxious dust, chemicals, fibres, and fumes from the destruction, and that got into their lungs.

Additionally, it has been found to have caused over 60 types of cancer and around two dozen other health conditions that can be directly linked to the days and weeks after 9/11. And it wasn’t just those at ground zero who were affected because the dust travelled around 44 miles downwind, and lots of people breathed it in.

Developing Physical and Mental Health Issues Are Causing Death

Most of the problems that are happening and causing death for those who responded to or survived the 9/11 attacks didn’t happen in the days and weeks, or even in the months after the attacks. The illnesses and mental health issues developed over time as all the contaminants got into the bodies and then started developing until the symptoms showed up.

PTSD is also a problem that sometimes doesn’t kick in until after the traumatic event as well, and while many people know about the physical issues we can’t forget about the mental issues that many of those who were at the attacks are dealing with. Survivor guilt, anxiety, depression, and other mental health issues are starting to grow as well

The Statistics Right Now

412 responders died on the day of the attacks, but now almost 3,500 have been noted to have passed away, primarily due to cancers or aerodigestive illness. The respiratory and upper digestive tract issues are the leading cause of death, followed by cancer, and death by mental health issues.

Additionally, the cases of Leukaemia are starting to rise among those first responders enrolled in The World Trade Centre Health Program, due to the exposure to the benzene jet fuel which was all around ground zero, and benzene has been proven to be linked to Leukaemia.

With the rise of other cancers related to asbestos as well, monitoring the health of survivors is something that organizations will continue to do.

Make Sure To Never Forget

For the first responders who are still dealing with the physical and mental traumas and effects of the September 11th attacks and the aftermath, they are remembering that event every single day of their lives, not just on the anniversary.

If you feel like you want to give to them and help them out, you should, because it will be a reminder to them that you haven’t forgotten either.

A Doctor with his arm crossed wearing his uniform and equipment

The Wound Closure Solution of the Future

With the effective treatment of wounds from sores to lacerations, Pathelen Health Care is the company behind the Pathelen Hybrid medical device, a treatment that focuses on encouraging the healing process. It does this by ensuring that any biofilms that prevent the formation of new tissue are removed, reducing the risk of infection and increasing the effectiveness of the body’s ability to recover from the wound. All of this, as well as its client service abilities, has earned it the title of ‘2022’s Most Innovative Biotech Company’ in Switzerland & 2022’s Awards for Excellence in Innovation.

With a core flagship product around which everything else has been created, Pathelen Health Care’s focus has been on its Pathelen Hybrid since its inception. Nominally, Pathelen Hybrid is a medical device that has been registered with SwissMedic and the USA FDA as an exemplary device for use in non-healing chronic wounds. Built to stimulate the healing time of such wounds as diabetic foot ulcers, ulcus cruris, and bed sores, the Pathelen Hybrid has its uses in ensuring that potentially damaging wounds are taken care of in a way that avoids the condition of the body worsening. In this way, use of the device has prevented amputation by ensuring the wounds are taken care of in a timely manner.

Critically, as a superabsorber, this product’s main draw is its ability to deal with any discharged liquid that a wound creates, making sure that it doesn’t linger around the sore and cause increased danger of infection or sepsis. Hygienic, utilitarian, and safe to use, it ensures that every medical professional who comes into possession of the device knows how to use it, but has also worked hard to ensure that the device is not overly complicated in any way, shape or form. In healthcare – especially when dealing with open wounds – time is often of the essence, especially when amputation is at stake; thus, it has strived to cut the fat from the process.

Specifically, its main target is the removal of biofilms that prevent the formation of granulation tissue. First and foremost, the prevention of granulation tissue is what prevents a wound from closing and can mean additional danger for a patient in terms of the wound getting worse, making it a longer and more painful healing process. Thus, the superabsorbent properties of Pathelen Hybrid take the uncertainty out of it, ensuring that biofilms are kept to a minimum after its application once the wound is clean of debris.

Granulation tissue is normally formed after 3-5 days, which leads to a successful complete closure between 3 and 8 weeks depending on the size and severity of the laceration or sore. Moreover, with a success far above the norm for medical devices of its kind, it has gone above and beyond the expectations of the medical community for it at every turn, with no side effects observed and no added complications thanks to the use of the Pathelen hybrid device. Instead, patients it has been used on have reported back with successful wound closures within the forecasted time and a good experience with it that has allowed it to become a staple of the hospitals and medical facilities it has provided its medical devices to.

In this manner, it has been able to achieve its goals through its own innovations, developments, and tenacity, something that it will be continuing to do long into the future. This dedication to constant improvement has vastly further endeared it to the medical industry and the international medical community, as the smallest change in variable could be the difference between a patient keeping a limb and losing it.

If the Pathelen Hybrid is applied within a timely manner, its usefulness in saving life and limb truly cannot be overstated. Going forward, Pathelen looks forward to continuing to improve and redevelop the Hybrid as it grows as a company, ensuring that its clients and their patients are the ones who benefit from the ever-growing and changing developments involved in the wider world of medical science and its specific fields. A big part of this will be working to be able to address the treatment of chronic wounds with treatments that do not contain pharmaceutical products.

By addressing such things with medical devices instead of ingestible or bloodstream delivered products, a clinic or hospital can increase the amount of people their various investments can treat safely, as with a medical device there is far less risk of allergic reaction or adverse side effects. This non-pharmaceutical delivery method of treatments has, therefore, made itself a more and more popular staple of the modern medical industry, one that will only be seeing more and more investment as it moves forward into the future.

Moreover, its patented manufacturing process can achieve such things at a higher success rate and lower cost than most pharmaceutical products, making for a deeply trusted product that has thrust Pathelen into pre-eminence. With this notoriety has come further trust, respect, and custom from clinics, hospitals, health centres, and clinicians, something that it sees only increasing as time goes on, especially given its propensity for working to keep Pathelen Hybrid at the top of its game.

For business enquiries, contact Bijan Sabet from Pathelen Health Care via their website –                                    

Pathelen product
Pathelen Hybrid
A Doctor standing and pointing at healthcare icons

Pioneering The Future of Effective Wound Care Solutions

The multi-award-winning company, Kent Imaging Inc., is a leading Medtech firm based in Calgary, Alberta, Canada. The company’s technologies – namely SnapshotNIR – are enabling clinicians to drive better outcomes in wound care, limb preservation, and surgery, with its diagnostic-driven imaging technology that assesses tissue oxygenation. Consequently, Kent Imaging has, once again, earned itself the esteemed title of Best Medical Imaging Technology Development Company, 2022 – Canada.

Effective wound management stems from consistent, in-depth wound healing monitoring and persistent therapy. Tissue oxygenation is a key indicator in a wound’s capacity to heal and tracking how this healing is progressing, as the delivery and uptake of oxygen in the tissue plays a fundamental role in cellular function and tissue epithelialization. Traditional equipment used in the observation of tissue perfusion and oxygenation is often large, immobile, and expensive. It is, in essence, incredibly limiting. As a result, patients are oftentimes wrapped up in lengthy appointments, invasive protocols, and a lack of accessibility. Additionally, many of these devices on the market only measure perfusion in the large vessels. SnapshotNIR measures tissue oxygenation in the critical microvascular network.

A Canadian company, Kent Imaging Inc., is on a crusade to optimise the technology utilised in this area. As such, Kent has established itself as an innovator, specialising in the production and marketing of advanced imaging equipment for wound care, limb preservation and surgical applications. Over the years, the company has filed multiple patents for ground-breaking technologies, with the goal of aiding both national and international healthcare systems.

Its flagship product, SnapshotNIR, serves as the latest generation of near-infrared tissue oxygenation imaging. The portable and lightweight technology is a far cry from the clunkiness of its predecessors and as easy to operate as a point-and-shoot camera, therefore able to be seamlessly integrated into clinical and surgical workflows. Furthermore, it is a wholly non-invasive piece of technology – SnapshotNIR uses no dyes or injectables, no consumables, and needs no direct patient contact to capture images wherever the patient is situated.

Supported by over two decades of research, SnapshotNIR uses near-infrared (NIR), reflectance-based technology. With this technology, SnapshotNIR measures relative amounts of oxygenated and deoxygenated hemoglobin in the microcirculatory network where oxygen exchange is happening. With a simple click of a button, clinicians are provided with a clear, easy to read, tissue oxygen saturation map that can provide valuable insight to help make informed, patient-centric medical decisions.

The SnapshotNIR device has a variety of applications, and can be used in cases of wound care, limb preservation, and reconstructive surgery. To provide some examples, the device can be leveraged in hyperbaric oxygen therapy (HBOT) to qualify patients for this advanced treatment modality, and then to assess the effectiveness of this treatment over the prescribed number of sessions. This is extremely valuable from both a time and economic standpoint as it can assist in patient compliance and enable the documentation of continued therapeutic success or the end of treatment. SnapshotNIR can be used to provide insight into the adequate preparation of a wound bed for the application of advanced therapies and then continue with the documentation of the efficacy of the therapy. In the interoperative environment, Snapshot can indicate the level of oxygenation in a surgical flap to provide insight into the likelihood of flap survival. This can impact decisions made while still in the OR. Within limb preservation, for instance, time is of the essence and the identification of poor tissue oxygenation in the peri-wound and surrounding tissues can serve to expedite vascular referral and intervention. In the United States alone, statistics show that every 30 minutes, $1 million is spent on diabetic foot complications, and 80% of non-traumatic amputations are a result of peripheral arterial disease (PAD) – over 50% will die within the first five-years of amputation. Kent Imaging’s solution means that access to non-invasive vascular assessments is increased, not only saving limbs, but potentially lives.

Additionally, the product enables clinicians to provide a greater standard of care to patients. Healing chronic wounds can often be a slow and frustrating process as wounds can be deceiving. In many instances, the status of the wound healing progress cannot be fully evaluated with visual inspection alone. With SnapshotNIR, practitioners gain insight that allows them to offer patients timely, informed, and, in some cases, life-saving solutions. This technology provides real-time insight through non-invasive, accurate and actionable data, which can result in better patient compliance and more positive outcomes.

The impact that SnapshotNIR has had has been significant– patients and clinicians alike have nothing but high praise for the product, and these testimonies are displayed across Kent’s website. Dr. Duane Cumberbatch has used the technology in a plethora of cases, and for one of his patients, an elderly woman suffering from chronic vascular wounds on each of her ankles, it forged almost unprecedented results. After suffering from these wounds for over six years, thanks to SnapshotNIR and Dr. Cumberbatch’s treatment, within six months of her first visit, her ankles were almost completely healed.

It is clear that Kent Imaging’s SnapshotNIR offers multiple benefits to both its users and their patients. Dr. Duane Cumberbatch’s experience with the product is mirrored within additional expert testimonies, including that of the Save a Leg, Save a Life Foundation. The organisation specialises in building awareness around the issues, care requirements and potential complications that can arise from diabetes or PAD-related chronic wounds.

The Foundation is now utilising SnapshotNIR in its community outreach screening events. “To be able to use a screening device like Snapshot that can give us information in a short amount of time is invaluable. As we grow our program and do more events around the country and elsewhere, wherever we have technology at our screenings, I think everyone benefits,” summarises Dr. Desmond Bell, a key player, and the creator of the foundation. The SnapshotNIR device is an exciting advancement in wound care technology. There is an increasing amount of evidence that displays the technology’s positive impact on client outcomes and the work clinicians can fulfil. In turn, Kent Imaging is changing the future for wound care, limb preservation, and reconstruction patients.

For business enquiries, contact Sandra Jenks at Kent Imaging Inc, via the website –

Pierre Lemire
Cylera presenting at convention

Healthcare Cyber Security Company of the Year – UK

An ‘Internet of Things’ platform that allows medical facilities to perform at peak efficiency without fear of cyber-attack, Cylera offers defence and synergy in a holistic fashion. Having worked hard to develop the best solution in the UK for remote, digital, and top-down medical device management in a way that doesn’t interfere with uptime or leave the facility open to infiltration, clients from large hospitals and small local health centres alike have lauded Cylera as an invaluable part of keeping the medical machine – both technologically and metaphorically – running smoothly.

Cylera, an industry leader when it comes to next-generation IT, IoMT, and OT cybersecurity, has been making a name for itself across the industry vertical with its hard-working team and exemplary solutions. Nominally, it has been developed to provide the strongest, most advanced, and most reliable healthcare Internet of Things solutions, alongside the best cybersecurity risk management solutions for the industry, especially when it comes to the defence of medical devices. Its focus on healthcare has certainly made it a front-runner, able to give clients peace of mind that the technology they use to help their patients is secure. Fundamentally, the Cylera platform through which these solutions are delivered ensures the strongest and most advanced IoT work is made available to its clients, discovering and securing the entire connected environment across an enterprise’s technological infrastructure.

Covering the overall structure, the medical devices found therein, and the building operations systems of a client’s facility, Cylera’s platform has been built for IT and clinical engineering both. Thus, it covers asset identification and management, network analysis, risk assessment, network segmentation, threat detection, intelligence, operational analytics and fleet optimisation, and has become well known for its excellence in each of these facets of its work, becoming a trusted provider of NHS trusts across the UK. Whether its clients specialise in acute, community, or mental health, Cylera’s technology enables it to stay focused on the patients, helping it to keep its medical devices cyber-safe and operational. This is something that its clients often mention in reviews.

Critically, its customers can trust the level of diligence and expertise that goes into the development of each and every one of its services, as well as its dedication to keeping its finger on the pulse of new developments and innovations in its industry so that it can remain staunchly competitive. Having seen significant growth in the market whilst keeping an eye on the trends therein, it has noted a prevailing spike in growth that began in the early months of 2021. Here, many NHS trusts flocked to Cylera for new and better cybersecurity solutions to help them handle the brunt of the oncoming challenges, benefitting hugely from the resulting increased security in their medical devices and healthcare infrastructure, meaning they have one less thing to worry about in an era of ever-evolving new concerns.

This award, for Cylera, is further proof that it is on the right track with its efforts, especially combined with 2021’s growth spurt. Having made itself a trusted partner to many healthcare providers, the third-party recognition granted by awards such as this signals the start of even more increasingly invaluable growth, ensuring that clients never need to just take its word for it when it comes to the exemplary nature of its services. Instead, they can trust the endorsements given to it by awards committees and previous clients both, able to peruse the various different reviews and referrals it has received over the years. Additionally, due to the industry it works within, many of its clients come to it through word-of-mouth referral by fellow professionals in healthcare.

Furthermore, its focus on healthcare allows it to stand out from its competitors, as it has built itself to specifically fit around the challenges of modern healthcare infrastructure and the requirements involved. Crucially, the specificity of its technology makes it the most reliable IoT service that a medical facility can purchase, the depths of its insights and the understanding of clinical and IT/SOC workflows it is able to display being totally second to none. It is also able to develop unique policy generation, customer collaborated design, and risk-free clinical systems or processes, able to scale this up or down to fit any scale of organisation or facility from the largest hospitals to the smaller, more locally focused practices.

Additionally, many vendors of IoT technology are actually providing re-purposed solutions. Often, these are generalised technological offerings that cannot adequately safeguard uptime, meaning they are unreliable when it comes to critical medical device management, enterprise IoT systems, and specialised healthcare environments, which can be incredibly dangerous should an attack catch a client unawares. These solutions give a ‘theatre of security’ style illusion whilst actually safeguarding nothing.

In contrast to such things, Cylera’s efforts are based around three key technological capabilities, providing the basis of the granular detail that it has been able to incorporate into its highly advanced, specific, and well-developed systems, all of which it is willing to talk a customer through in detail. Firstly, it works hard to incorporate adaptive datatype analysis into itself. This is something that Cylera has been working hard on for many a year, resulting in a patented and proprietary method of identifying IoT devices and extracting data whether known or unknown from the relevant sources, all whilst IoMT are introduced and moved throughout the environment.

Cylera uses this to be able to tell a client far more about the status of the device, where it is, and how it is communicating with other systems; something that many of its competitors either cannot do or do not handle nearly as well. This is further bolstered by its Internet of Things Device Emulation Engine, or ‘Digital Twin’. Regarding this specifically, its patented Device Emulation engine creates digital twin simulations of the live device in the platform itself, allowing accurate configuration and behaviours that keep a close eye on the actual device’s status. Maintained in real time as the device changes and as fluctuations occur in the live environment, Cylera can ensure industry-leading vulnerability scanning without jeopardising device uptime or clinical continuity, ensuring that the medical facility in question can continue to run smoothly.

Third and lastly – but certainly not least – amongst Cylera’s technological capabilities is its Intelligence Database. Cylera’s CyLabs provision is a unique blend of cutting-edge proprietary research into healthcare devices and the cross-industry threats that such healthcare delivery organisations face, benefitting the customer to include an understanding of how risks may affect the business. By implementing software born out of this deep understanding of the wider clinical context, Cylera allows clients to continue their expert delivery of healthcare solutions, giving them invaluable peace of mind that they will have no cybersecurity threats to take away from this such as unpatched devices or ratings without context awareness.

The most recent development in the Cylera platform has recently become the new Cyber Alert Dashboard. Nominally, this has been developed based on the number of specific requests that the business receives on a daily basis, pushing it to respond by rising to the challenge and developing a system specific to the needs of NHS Trust customers. Having shown its diligence, professional acumen, and tenacity when it comes to serving such clientele, the new dashboard highlights whether the Trust has any equipment affected by the NHS Digital Cyber Alert security notifications and guides them on how to resolve or mitigate against each threat, issuing cyber alerts to health and care organisations in order to keep them up to date.

This has, critically, allowed Cylera to develop a kind of ‘early warning system’. From weekly threat bulletins to immediate, high-severity alerts, Cylera’s clients have been benefitting from a new, comprehensive, and holistic answer to cybersecurity awareness, allowing responses to be timely and specific enough to resolve risks before they become threats in the first place. Naturally, this is something that has further increased Cylera’s notoriety in the industry, setting it up as a cornerstone of the modern NHS’s working infrastructure and a critical linchpin between the facilities scattered all over the UK.

Over the last few years, healthcare providers have also become increasingly targeted by sophisticated cyberattacks. This, combined with the ever-evolving threats that cyberattacks can pose, as well as additional pressure put on the medical industry by the pandemic has made the cybersecurity and cyber defence of facilities even more pivotal than ever before. Nominally, many of these attacks directly focus on the connections that medical professionals and devices have to the IoT.

Cylera wishes to make the IoT and solutions therein as safe and secure as possible, not just for specific elements of the medical sector, but for the entire industry vertical across all manner of scales and specific healthcare provisions. Becoming the safeguarding watchdog for networks, access protected data, patient care, and other such services, NHS Digital has continued to make Cylera its core stalwart and defender, helping it to raise the bar for healthcare’s data security requirements. Additionally, it has also been expanding the scope of the identifications and monitoring that connected medical devices can achieve.

As more and more NHS trusts look to adhere to new DSPT standards, Cylera is excited to be serving a new boom in interest in both its platform and the how’s and why’s behind its services, able to show the benefits that a facility can glean by trusting a cybersecurity expert. Moreover, as a constantly developing and tenacious company, it has been able to update its specific capabilities to be perfectly in line with the issues these new customers wish to see resolved or mitigated, for instance being able to provide a map to the majority of DSP toolkit requirements. This aids the acceleration of how quickly NHS clients can prepare their submission, backed up by all relevant evidence needed for validation.

Like many start-ups, it is fully focused on collaboration and achieving a set vision. This – safeguarding what matters most – has made it a true industry darling and a gem in the medical sector throughout the UK, something that will be continuing to be true long into the future. Taking care of the professionals, and by proxy, the patients, Cylera’s efforts ensure that medical facilities can operate quickly, efficiently, and without fear of disruption from outside sources, able to rest assured that even though cyberthreats evolve on a daily basis, so does Cylera.

For business enquiries contact Katherine Brocklehurst via the website –                                          


Dedicated Developments


Cambridge-based medical device company Medovate – the ‘Best Medical Device Innovation Development Company – 2022’ for the UK, is a business with a unique – and now proven – business model, working closely with clinicians to support the development of NHS-developed innovation. Spun out of the NHS in 2017, Medovate has made a name for itself for its ability to identify and develop high potential innovations into award-winning products which are available for the benefit of patients and clinicians across the globe.

The company is a dedicated medical device development vehicle for the NHS and prides itself on working closely with clinicians to develop valuable medical technology innovations with the potential to improve patient safety. Using its exceptional expertise to help guide them through the entire, and often complex, development pathway – from design, manufacturing, regulation and quality, feasibility testing, and clinical trials, through to product launch, marketing and distribution.

In the space of just four years ago, the company has established a proven platform to bring medical products to market and has pressed ahead with licensing and building a portfolio of medical devices to improve patient safety relating to the specialist areas of anaesthesia, airway management, critical care and surgery.

Today a celebrated, multi-award-winning company, Medovate has achieved a great deal in its first few years and is now confidently looking forward, building on all it has achieved so far, expanding its product portfolio and planning new product launches.

Through its unique medical device development pipeline, the company aims to improve patient care and safety by supplying innovative MedTech solutions to global healthcare systems, which are facing some of the most pressing challenges of the modern era.

The pandemic has indeed created an environment of enhanced safety measures. At the heart of Medovate’s expanding portfolio is its revolutionary technology SAFIRA® (SAFer Injection for Regional Anaesthesia) – its first product to be brought to market. The device – already launched in key markets across the world, from the United States to the UK and Europe, Australia and New Zealand – has been designed to make injection during regional anaesthesia safer.

During the COVID-19 pandemic, the European and the American Societies of Regional Anaesthesia both produced joint COVID-19 recommendations stating that regional anaesthesia should be preferred over general anaesthesia as the need to minimise aerosol-generating procedures (AGPs) took precedence.

The device, which has been designed in collaboration with NHS clinicians, includes a built-in safety mechanism to automatically limit injection pressure, helping to reduce the risk of nerve damage and promote patient safety. As the practice of regional anaesthesia grows globally, the use of SAFIRA® for regional anaesthesia procedures has the potential to make a significant impact on improving patient safety.

The system has since been developed to include the option of using an NRFit® connector, together with either a foot or palm operator, offering greater choice and versatility to clinicians. Medovate has successfully secured CE mark approval and FDA clearance for the SAFIRA® system.

As impressively, the game-changing technology has also been found to have potential to make a difference in veterinary care and this is being explored with partners in global veterinary markets to see how the technology could make regional anaesthesia safer for animals. A male lion at the Five Sisters Zoo (FSZ) in Scotland became the first-ever animal in the world to have dental surgery using SAFIRA® last June.

The technology is fast attracting considerable attention in regional anaesthesia circles and developing a reputation as a device of choice for supporting safer regional anaesthesia practice. SAFIRA® was awarded the prestigious ‘Patient Safety Innovation of the Year’ at the HSJ Awards in September 2021 – a recognition of its capabilities as an outstanding example of healthcare innovation which has clearly improved safety for both patients and staff, and a further stamp of approval for Medovate’s unique business model.

Having successfully launched its first FDA-cleared and CE Mark certificated medical device in multiple international markets, Medovate now has agreements in place to make the technology available in 60+ countries over the next few years. The company also has a number of exciting additional innovations in the pipeline, including their novel HME safety device HUMIDICARE®, a novel heat and moisture exchanger (HME) which has a safety engineered warning system to promptly visually alert staff to a dual humidification error in a ventilation circuit, helping prevent potential harm to patients.

In the field of critical care, the company has developed Glucosave®, a patient safety solution designed to help prevent incidences of unnecessary administration of insulin following blood sampling where a glucose containing flush solution has been inadvertently connected, something which can have serious consequences for patients.

With the wind firmly in their sails, Medovate is also actively pursuing further regulatory approvals and distribution agreements for other key markets across Asia-Pacific, Canada and South Africa. With further regulatory approvals for the promising technologies in the Medovate portfolio imminently anticipated, and additional technologies approaching clinical trials and market launch, this is just the beginning for this fast-growing company, which has grown from an initial team of 2 to a team of 16, including a consultant based in the US – the home of its first product launch.

Medovate now continues to work with distributor partners who are global leaders in their field to bring its innovations to market, such as Vygon in markets including Europe and the UK; and Mercury Medical, through which it is working to distribute SAFIRA® across the whole of the United States.

The company also has a co-promotional partnership agreement with Konica Minolta Healthcare Americas Inc. – a world-class provider and market leader in medical diagnostic imaging – to promote best practice in ultrasound guided regional anaesthesia across the US. The partnership was formed to highlight the provision of Ultrasound Guided Regional Anaesthesia’ and how the ground-breaking SAFIRA® can be used in conjunction with Konica Minolta Healthcare Americas’ Inc. range of pioneering ultrasound solutions.

Today Medovate continues to work with partners to uncover further NHS innovations to add to its portfolio, keep the positive cycle of developing NHS innovation going and realising its potential to help support further NHS innovation; while also raising awareness of the amazing innovations generated by the NHS which can benefit clinicians and patients beyond the UK. Through its partners and co-promotional partners, the company continues to work towards its vision to promote patient safety through healthcare innovations arising from the UK’s world leading institution – which, as an additional benefit, remains a key stakeholder for the organisation. The company operates a unique model ensuring the Trusts where its new device ideas originate receive a share of the profits from successful commercialisation, thus helping it to feed into the healthcare innovation cycle in an exceptional way.

For further information, please visit

Medical Innovation

New Material Paves the Way for Remote-Controlled Medication and Electronic Pills

Medical Innovation

Biomedicines are produced by living cells and are used to treat cancer and autoimmune diseases among other things. One challenge is that the medicines are very expensive to produce, something that limits global access. Now researchers from Chalmers have invented a material that uses electrical signals to capture and release biomolecules. The new and efficient method may have a major impact in the development of biomedicines and pave the way for the development of electronic pills and drug implants.

The new material is a polymer surface* which at an electrical pulse changes state from capturing to releasing biomolecules. This has several possible applications, including use as a tool for the efficient separation of a medicine from the other biomolecules that cells create in the production of biological medicines. The results of the study were recently published in the scientific journal “Angewandte Chemie”.

Biomedicines are very expensive to produce due to the lack of an efficient separation technique, and new techniques with a higher drug yield are required to reduce production costs and ultimately the cost of treating patients.

“Our polymer surfaces offer a new way of separating proteins by using electrical signals to control how they are bound to and released from a surface, while not affecting the structure of the protein,” says Gustav Ferrand-Drake del Castillo, who publicly defended his doctoral thesis in chemistry at Chalmers and is the lead author of the study.

The conventional separation technique – chromatography – binds biomolecules tightly to the surface and strong chemicals are required to make them release, which leads to losses and a poor yield. Many new medicines have proved to be highly sensitive to strong chemicals, which creates a major production problem for the next generation of biomedicines. The lower consumption of chemicals results in a benefit to the environment, while the fact that the surfaces of the new material can also be reused through several cycles is a key property. The process can be repeated hundreds of times without affecting the surface.


Functions in biological fluids

The material also functions in biological fluids with a buffering capacity, in other words fluids with the ability to counteract changes in the pH value. This property is remarkable since it paves the way for the creation of a new technique for implants and electronic “pills” that release the medicine into the body via electronic activation.

“You can imagine a doctor, or a computer program, measuring the need for a new dose of medicine in a patient, and a remote-controlled signal activating the release of the drug from the implant located in the very tissue or organ where it’s needed,” says Gustav Ferrand-Drake del Castillo.

Local, activated drug release is available today in the form of materials that change their state in the event of a change in the surrounding chemical environment. For example, tablets of pH-sensitive material are produced where you want to control the release of a drug in the gastrointestinal tract, which is an environment with natural variations in pH value. But in most of the body’s tissues there are no changes in pH value or other chemical parameters.

“Being able to control the release and uptake of proteins in the body with minimal surgical interventions and without needle injections is, we believe, a unique and useful property. The development of electronic implants is only one of several conceivable applications that are many years into the future. Research that helps us to link electronics with biology at a molecular level is an important piece of the puzzle in such a direction,” says Gustav Ferrand-Drake del Castillo.

Another advantage of the new method is that it does not require large amounts of energy. The low power consumption is due to the fact that the depth of the polymer on the surface of the electrode is very thin, on the nanometre scale, which means that the surface reacts immediately to small electrochemical signals.

“Electronics in biological environments is often limited by the size of the battery and the moving mechanical parts. Activation at a molecular level reduces both the energy requirement and the need for moving parts,” says Gustav Ferrand-Drake del Castillo.


The breakthrough began as a doctoral thesis

The research behind the technique was conducted during the period when Ferrand-Drake del Castillo was a doctoral student in Chalmers professor Andreas Dahlin’s research team in the Division of Applied Surface Chemistry. The project involved polymer surfaces that change state between being neutral and charged depending on the pH value of the surrounding solution. The researchers then succeeded in creating a material that was strong enough to stay on the surface when subject to repeated electrical signals, while also being thin enough to actually change pH value as a result of the electrochemistry on the surface.

“Shortly afterwards we discovered that we could use the electrical signals to control the binding and release of proteins and biomolecules, and that the electrode material works in biological solutions such as serum and centrifuged blood. We believe and hope that our discoveries may be of great benefit in the development of new medicines,” says Andreas Dahlin.

In the past year, the Chalmers researchers’ results have been passed on to product development, carried out by the spin-off company Nyctea Technologies. The company already has customers among leading pharmaceutical researchers and companies.

*Polymers are chemical compounds that consist of very long chains made up of repeated smaller units. Common plastics are a form of polymer.

Health Monitoring

Best Health Monitoring Technology Specialists 2022

Health Monitoring

Technology is the future of the care industry. Indeed, with the numerous challenges that the industry is facing – largely the increase in demand – it is inevitable that technology will begin to seep into residential homes, residences, and care facilities. Lilli is one of the leading companies working within this area, and its primary mission is to allow people to live in their homes for longer whilst continuing to receive non-invasive care, therefore increasing independence, and bolstering quality of life.

Lilli, a company that offers proactive health monitoring technology, has grown exponentially over the past couple of years. Indeed, the company achieved a 50% oversubscription of its Pre-Series A funding round, which raised £4.5 million in March 2021. Lilli also acquired a chief strategy officer, chief commercial officer, chief technology officer, and a chief medical officer, boosting the team from four members in August 2020 to 22 by the end of 2021. A notable achievement during a turbulent time in which everyone was working remotely.

The goal behind Lilli is simple – to enable millions of people to live independently in their own homes for as long as possible. As this issue begins to creep further into the public sphere, primarily due to an ageing population and the rising pressure on resources in the health and social care sector, Lilli has decided to take action. Through the use of SaaS technology, the company hopes to revolutionise remote monitoring for home care by moving away from conventional, reactive, alarm-based approaches to a highly accurate, preventive methodology.

How does Lilli aim to do this? Largely through utilising behavioural analytics and sensor technology to create a baseline of an individual’s typical behaviour. In essence, the company places sensors within the home that monitor a range of actions – movement, temperature, night-time activity, and eating and drinking habits, for example. When the resident deviates from this routine or demonstrates wildly abnormal behaviour, Lilli’s technology sends alerts to the care circle, providing them with the chance to investigate and make that all-important early intervention.

Such technology is beneficial within the homes of the elderly or the vulnerable, namely those with learning disabilities or long-term neurological or mental health conditions. Lilli has cultivated a diverse clientele, working to aid those who have a high degree of independence, and also those that need a little bit of extra help. Either way, Lilli hopes to bolster their independence and allow them to live a full life without any significant intrusions. As such, Lilli gains much of its business through local authorities, housing associations, private care organisations and the NHS, because its technology allows for them to allocate resources to areas where it is needed most. Consequently, Lilli’s technology saves time, money, and resources, with benefits radiating from the organisation to the resident.

Subsequently, the company is constantly searching for ways to advance its technology and is constantly innovating and refining its technology in relation to what works in the real world. A significant portion of this conducted through working alongside its clients to understand where their pain-points are and how best to resolve them. Henceforth, Lilli maintains a close relationship with decision-makers and frontline staff alike in the social care sector, and it uses these insights to inform its product development so that it continues to meet the needs of its clients.

Over the past few years, the care industry has been under a great strain due to greater demand and a lack of funding. A Freedom of Information request from The Observer newspaper revealed that across 96 English councils there were 60,664 hours of undelivered home care in December 2021, compared with 15,905 in April. That’s a big increase in shortfall that has a major impact on individuals. As a result, the UK Government plans to invest £150 million on driving greater adoption of technology and digitisation in social care, with the aim of supporting independent living. This is further complimented by Build Back Better policy saw the government pledge to invest £5.4bn in adult social care over the next three years, including £1bn for initiatives such as improvement of digital and technological infrastructure.

At the forefront of the industry, Lilli will benefit greatly from these investments, and therefore, it has a bright future ahead. Throughout the upcoming year, for example, Lilli will be entering an execution phase, in which it will be looking to further extend its offering to more housing associations and the wider private care space, such as domiciliary and homecare agencies. In the long-term, the company has plans to extend its operations overseas, with plans to launch in both the United States and Europe.

For further information, please contact